Neurofibromatosis type 1, also known as von Recklinghausen disease, is the most common type of neuro-cutaneous disorders. Half the patients inherit the disease in an autosomal dominant (AD) manner and the other half are the result of sporadic mutations in the NF1 gene, a tumor-suppressor gene located on chromosome 17 [7]. Neurofibromin, the product of NF1 gene, is expressed in all cell types but has highest concentrations in glial cells, neurons, leukocytes, and Schwann cells [8]. This protein belongs to the GTPase activating protein family which inactivates the RAS signaling pathway by hydrolyzing the attached GTP to RAS protein. Any production of malfunctioned neurofibromin or its decreased production results in impaired RAS oncogene inhibition. Increased RAS activity leads to uncontrolled cell growth [9]. The first dysfunctional NF1 allele is inherited as a germline mutation and an acquired mutation in the second allele during a somatic event leads to development of neoplasms. This loss of heterozygosity occurs during somatic rearrangement, recombination and deletion which may affect other genes located on chromosome 17 including P53, epidermal growth factor 2 (HER2), topoisomerase II alpha (TOP2A) and breast cancer gene 1 (BRCA1). Alongside NF1, other mutated genes collaborate in pathogenesis of neoplasms, most notably of the nervous system [10]. Among the nervous system neoplasms, NF1 patients are particularly prone to malignant peripheral nerve sheath tumors (MPNST), optic pathway gliomas and pilocytic astrocytomas [11]. Comparing to the general population, NF1 patients are at an increased risk of malignant gliomas as well benign ones [5].The risk of malignancy in NF1 patients has been reported to be 5 to 29% in several studies [12,13,14].
Herein, we present a case of NF1 diagnosed with multifocal left cerebellar GBM. GBM is the most common primary malignant brain tumor and the most aggressive type among gliomas with less than 5% survival rate beyond 36 months [15]. The majority of GBM patients develop the neoplasm sporadically; however, patients with disorders such as neurofibromatosis, Turcot syndrome, and Li–Fraumeni syndrome are genetically predisposed to sustain GBM [16]. Common molecular alterations in GBM include increased copies of EGFR gene, mutated P53 gene, inactivation of RB gene, and mutations in IDH-1 gene alongside other mutations [17, 18]. Abnormal NF1 gene, either mutated or deleted, is frequent in human GBM, as 23% of GBMs were reported to harbor aberrations in the NF1 gene [19]. Although NF1 patients usually present with low-grade gliomas, a handful of GBM tumors associated with NF1 have been reported.
Pál and colleagues, in 2001, reported a 37-year-old NF1 patient who died of progressive multiple sclerosis whose autopsy revealed a right hemisphere glioblastoma tumor which was not symptomatic during her life [20]. In another article in 2008, a 28-year-old NF1 patient diagnosed with lobar cystic GBM was presented. The patient was managed with surgical resection and adjuvant chemo-radiation therapy with 41 months survival [21]. Huttner and colleagues analyzed the molecular biology beyond GBM tumors in five NF1 pediatric patients. All five tumors demonstrated P53 mutation and increased EGFR copy numbers. The study suggested a more favorable prognosis could be expected for GBM tumors in NF1 patients rather than the sporadic cases [22]. In another case report of a 32-year-old NF1 patient with GBM, the tumoral cells were strongly positive for GFAP and negative for EGFR. The patient was treated with surgical removal of the tumor and adjuvant chemo-radiation. He had no remarkable symptoms and tumor recurrence up to 9 months post-operation follow-up [23]. In another article, a 9-year-old NF1 patient was reported who died of GBM 3 days following initial diagnosis, warning physicians to follow tumors in NF1 patients closely [24].
Shibahara and colleagues reported a unique subset of GBM in four NF1 patients. None of the patients had mutations in isocitrate dehydrogenase 1 (IDH-1) gene, v-RAF murine sarcoma viral oncogene homolog B1 (BRAF) gene, and telomerase reverse transcriptase (TERT) gene promoter [25].
Cerebral hemispheres are the most frequent sites of GBM, while less than 5% of cases are located in infratentorial regions of the brain [6]. We reviewed the current literature regarding infratentorial GBM tumors in NF1 patients. Few instances of posterior fossa GBM in NF1 patients has been reported up to the year 2019. A 28-year-old NF1 patient was followed for a cerebellar mass believed to be a hamartoma. Later, due to worsened symptoms, the mass was resected and pathology reported two distinct tumors attached together, a neurofibromas and a GBM. On IHC staining, the first lesion was positive for S-100 mutation and the latter was positive for GFAP and 30% of cells harbored P53 mutation. The study suggested close follow-up of brain lesions in NF1 patients for potential development of high-grade gliomas. The Patient received standard surgical and chemo-radiational therapy but showed signs of tumor metastasis in right frontal lobe and died 6 months after the treatment [26]. In another report from India, a 6-year-old NF1 patient was diagnosed with cerebellar GBM and despite surgical intervention and chemo-radiotherapy died after 4 months [27].
The patient we presented in the current study was diagnosed with infratentorial GBM which is a relatively rare site to expect GBM. In the general population, supratentorial GBM is more frequent than the infratentorial ones, so we hypothesize the rarity of infratentorial GBM in NF1 patients might be secondary to this fact. Interestingly, the presented tumor had unique molecular findings including the lack of IDH-1 and P53 mutation with positive Ki67 in 5% of cells and low mitosis activity (1-2/Hpf). Due to the tumor’s low mitosis activity, we expected a relatively favorable outcome, as in a previous meta-analysis, low Ki67 positivity was the strongest factor associated with a better prognosis [28]. Accordingly, in the most recent evaluation which was 19 months after initial diagnosis, the patient had an acceptable performance score and the most recent brain MRI showed a slight decrease in size of the residual tumor and no recurrence of the resected one.
Despite the common concept of high probability of benign nature of brain tumors in NF1 patients, though rare, possibility of malignant gliomas in NF1 patients should be kept in mind. Most gliomas in NF1 patients follow an indolent clinical course. On the other hand, they are at an increased risk of developing malignancies; therefore we suggest close follow-up of brain mass lesions in NF1 patients and eminent surgical resection of lesions which grow quickly or induce neurological deterioration.
